MDxHealth SA (NASDAQ:MDXH) Q1 2024 Earnings Call Transcript

Michael McGarrity: Yes, Thomas. So we don’t break out margin by product, but we obviously — I shouldn’t say obviously, but part of our process before we introduce something is that we believe that it’s accretive to our business from an operating and gross margin perspective, day one, dollar one. There’s always a little bit of a ramp there, but it fits well into our P&L profile.

Thomas Vranken: Okay. And as a second question, I also wanted to zoom in a little bit on the OrbiMed financing agreement. Could you give any sentiment whatsoever as to how we should think about the interest rates perhaps as compared to the prior loan that was in place with Innovatus?

Michael McGarrity: Yes. Thomas, I think to Ron’s point, I think we would just refer you to all of our filings for the detail on the facility. But we think it is strong, both from a commitment and from a market perspective.

Operator: There are no further questions at this time. And ladies and gentlemen, this concludes today’s conference call. Thank you very much for your participation. You may now disconnect.